Literature DB >> 21856925

RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells.

Christoph S Nabzdyk1, Hope Lancero, Khanh P Nguyen, Sherveen Salek, Michael S Conte.   

Abstract

Survivin (SVV) is a multifunctional protein that has been implicated in the development of neointimal hyperplasia. Nuclear SVV is essential for mitosis, whereas in mitochondria SVV has a cytoprotective function. Here, we investigated the effects of RNA interference (RNAi)-mediated SVV knockdown on cell cycle kinetics, apoptosis, migration, and gene expression in primary cultured vascular smooth muscle cells (VSMCs) from the human saphenous vein. Primary Human VSMCs were obtained from saphenous veins and cultured under standard conditions. SVV knockdown was achieved by either small interfering RNA or lentiviral transduction of short hairpin RNA, reducing SVV gene expression by quantitative PCR (>75%, P < 0.01) without a loss of cell viability. Subcellular fractionation revealed that RNAi treatment effectively targeted the nuclear SVV pool, whereas the larger mitochondrial pool was much less sensitive to transient knockdown. Both p53 and p27 protein levels were notably increased. SVV RNAi treatment significantly blocked VSMC proliferation in response to serum and PDGF-AB, arresting VSMC growth. Cell cycle analysis revealed an increased G(2)/M fraction consistent with a mitotic defect; 4',6-diamidino-2-phenylindole staining confirmed an increased frequency of polyploid and abnormal nuclei. In a transwell assay, SVV knockdown reduced migration to PDGF-AB, and actin-phalloidin staining revealed disorganized actin filaments and polygonal cell shape. However, apoptosis (DNA content and annexin V flow cytometry) was not directly induced by SVV RNAi, and sensitivity to apoptotic agonists (e.g., staurosporine and cytokines) was unchanged. In conclusion, RNAi-mediated SVV knockdown in VSMCs leads to profound cell cycle arrest at G(2)/M and impaired chemotaxis without cytotoxicity. The regulation of mitosis and apoptosis in VSMC involves differentially regulated subcellular pools of SVV. Thus, treatment of VSMC with RNAi targeting SVV might limit the response to vascular injury without destabilizing the vessel wall.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856925      PMCID: PMC3213959          DOI: 10.1152/ajpheart.00089.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  20 in total

1.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.

Authors:  G Ambrosini; C Adida; D C Altieri
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

2.  Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration.

Authors:  J Sun; S O Marx; H J Chen; M Poon; A R Marks; L E Rabbani
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

3.  Cancer gene therapy using a survivin mutant adenovirus.

Authors:  M Mesri; N R Wall; J Li; R W Kim; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

4.  Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation.

Authors:  Jodi A McKenzie; Tong Liu; Agnessa G Goodson; Douglas Grossman
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

5.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

Authors:  Takehiko Dohi; Elena Beltrami; Nathan R Wall; Janet Plescia; Dario C Altieri
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis.

Authors:  Reiko Honda; Roman Körner; Erich A Nigg
Journal:  Mol Biol Cell       Date:  2003-05-29       Impact factor: 4.138

7.  Regulation of survivin function by Hsp90.

Authors:  Paola Fortugno; Elena Beltrami; Janet Plescia; Jason Fontana; Deepti Pradhan; Pier Carlo Marchisio; William C Sessa; Dario C Altieri
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

8.  Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis.

Authors:  Elena Beltrami; Janet Plescia; John C Wilkinson; Colin S Duckett; Dario C Altieri
Journal:  J Biol Chem       Date:  2003-10-27       Impact factor: 5.157

9.  Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function.

Authors:  Paola Fortugno; Nathan R Wall; Alessandra Giodini; Daniel S O'Connor; Janet Plescia; Karen M Padgett; Simona Tognin; Pier Carlo Marchisio; Dario C Altieri
Journal:  J Cell Sci       Date:  2002-02-01       Impact factor: 5.285

10.  Human survivin is a kinetochore-associated passenger protein.

Authors:  D A Skoufias; C Mollinari; F B Lacroix; R L Margolis
Journal:  J Cell Biol       Date:  2000-12-25       Impact factor: 10.539

View more
  6 in total

1.  Inhibitory effect of D1-like dopamine receptors on neuropeptide Y-induced proliferation in vascular smooth muscle cells.

Authors:  Yongqiao Zhou; Weibin Shi; Hao Luo; Rongchuan Yue; Zhen Wang; Wei Wang; Li Liu; Wei Eric Wang; Hongyong Wang; Chunyu Zeng
Journal:  Hypertens Res       Date:  2015-07-16       Impact factor: 3.872

2.  Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts.

Authors:  Christoph S Nabzdyk; Maggie C Chun; Hunter S Oliver-Allen; Saif G Pathan; Matthew D Phaneuf; Jin-Oh You; Leena K Pradhan-Nabzdyk; Frank W LoGerfo
Journal:  Biomaterials       Date:  2014-01-04       Impact factor: 12.479

Review 3.  Survivin - The inconvenient IAP.

Authors:  Dario C Altieri
Journal:  Semin Cell Dev Biol       Date:  2015-01-12       Impact factor: 7.727

4.  Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Ian F Pollack
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 5.  Current siRNA targets in the prevention and treatment of intimal hyperplasia.

Authors:  Leena Pradhan-Nabzdyk; Chenyu Huang; Frank W LoGerfo; Christoph S Nabzdyk
Journal:  Discov Med       Date:  2014-09       Impact factor: 2.970

Review 6.  RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.

Authors:  Christoph S Nabzdyk; Leena Pradhan-Nabzdyk; Frank W LoGerfo
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.